SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the 25th Annual H.C. Wainwright Global Investment Conference.
Presentation details are as follows:
Event: 25th Annual H.C. Wainwright Global Investment Conference
Date: Monday, September 11, 2023
Time: 10:00m ET
Webcast Link
Cidara’s presentation will be available on-demand from the above date/time in the investors section on the Company’s website at www.cidara.com. The replay of the presentation will be available for 90 days.
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs). These targeted immunotherapies offer the unique opportunity to create “single molecule cocktails” comprised of targeted small molecules and peptides coupled to a human antibody fragment (Fc). DFCs are designed to save lives and improve the standard of care for patients facing cancers and other serious diseases by inhibiting specific disease targets while simultaneously engaging the immune system. In addition, Cidara received FDA approval for REZZAYO™ (rezafungin for injection), which it has licensed to multiple partners to commercialize in the U.S. and ex-U.S. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
This email address is being protected from spambots. You need JavaScript enabled to view it.
MEDIA CONTACT:
Veronica Eames
LifeSci Communications
646-970-4682
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$48.30 |
| Daily Change: | -0.48 -0.98 |
| Daily Volume: | 759,410 |
| Market Cap: | US$528.880M |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
